Key Figures Q1 2024
|
SEK m, unless otherwise stated |
2024 |
2023 |
% Change |
2023 |
|
| Net revenues | 139.3 | 158.8 | -12.3% | 638.8 | |
| Cost of goods sold | -13.3 | -28.7 | -53.7% | -88.9 | |
| Operating expenses | -130.7 | -189.4 | -31.0% | -659.5 | |
| EBIT | -4.7 | -59.3 | 92.1% | -109.5 | |
| EBIT margin, % | -3.4% | -37.4% | 91.0% | -17.1% | |
| EBITDA | 15.9 | -41.1 | 138.7% | -32.5 | |
| Earnings per share, before dilution, SEK | -0.26 | -1.86 | -86.1% | -3.73 | |
| Earnings per share, after dilution, SEK | -0.26 | -1.86 | -86.1% | -3.73 | |
| Cash flow from operating activities | -18.9 | -61.6 | 69.3% | -95.0 | |
| Cash and invested funds | 198.0 | 278.9 | -71.0% | 171.0 |
Net revenues and EBIT per segment Q1 2024
|
|
Net Revenues |
EBIT |
||||
|
|
2024 |
2023 |
2023 |
2024 |
2023 |
2023 |
| Zubsolv® US product sales | 129.3 | 140.3 | 577.7 | - | - | - |
| Digital Mental Health Programs (DMHP) product sales | - | 0.0 | 0.1 | - | - | - |
| US Commercial– total | 129.3 | 140.3 | 577.7 | 31.9 | 37.9 | 152.3 |
| Abstral® royalties | 7.1 | 6.2 | 31.9 | - | - | - |
| Edluar® royalties | 2.7 | 1.3 | 10.8 | - | - | - |
| Zubsolv - ex US | 0.2 | 10.9 | 18.4 | - | - | - |
| HQ & Pipeline - total | 10.0 | 18.5 | 61.1 | -36.6 | -97.2 | -261.8 |
| Total | 139.3 | 158.8 | 638.8 | -4.7 | -59.3 | -109.5 |
Cash flow Q1 2024
SEK m |
2024 |
2023 |
2023 |
|
| Cash flow from operating activities | -18.9 | -61.6 | -95.0 | |
| Investment activities | -1.2 | 83.1 | 200.8 | |
| Financing activities | 43.3 | -7.8 | -70.1 | |
| Cash flow (excl exchange rate differences) | 23.2 | 13.8 | 35.7 | |
| Cash and cash equivalents | 198.0 | 142.4 | 171.0 |